{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:40:21Z","timestamp":1790476821537,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00406-026-02361-4","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:16:37Z","timestamp":1787973397000},"page":"3949-3961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study"],"prefix":"10.1007","volume":"276","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3344-1000","authenticated-orcid":false,"given":"Vassilis","family":"Martiadis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Raffone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Atripaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Pessina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Ignazio","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"d\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Cavallotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Olivola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Dell\u2019Osso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"2361_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT et al (2023) Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 22:394\u2013412. https:\/\/doi.org\/10.1002\/wps.21120","journal-title":"World Psychiatry"},{"key":"2361_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jama.2024.5756","volume":"332","author":"GE Simon","year":"2024","unstructured":"Simon GE, Moise N, Mohr DC (2024) Management of depression in adults: a review. JAMA 332:141\u2013152. https:\/\/doi.org\/10.1001\/jama.2024.5756","journal-title":"JAMA"},{"key":"2361_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12325-023-02700-0","volume":"41","author":"AJ Oliveira-Maia","year":"2024","unstructured":"Oliveira-Maia AJ, Bobrowska A, Constant E et al (2024) Treatment-resistant depression in real-world clinical practice: a systematic literature review of data from 2012 to 2022. Adv Ther 41:34\u201364. https:\/\/doi.org\/10.1007\/s12325-023-02700-0","journal-title":"Adv Ther"},{"key":"2361_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB et al (2021) Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry 178:383\u2013399. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081251","journal-title":"Am J Psychiatry"},{"key":"2361_CR5","doi-asserted-by":"publisher","first-page":"1394787","DOI":"10.3389\/fpsyt.2024.1394787","volume":"15","author":"M Di Vincenzo","year":"2024","unstructured":"Di Vincenzo M, Martiadis V, Della Rocca B, Arsenio E, D\u2019Arpa A, Volpicelli A, Luciano M, Sampogna G, Fiorillo A (2024) Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review. Front Psychiatry 15:1394787. https:\/\/doi.org\/10.3389\/fpsyt.2024.1394787","journal-title":"Front Psychiatry"},{"key":"2361_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M et al (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 75:139\u2013148. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3739","journal-title":"JAMA Psychiatry"},{"key":"2361_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M et al (2019) Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 176:428\u2013438. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19020172","journal-title":"Am J Psychiatry"},{"key":"2361_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","volume":"22","author":"M Fedgchin","year":"2019","unstructured":"Fedgchin M, Trivedi M, Daly EJ et al (2019) Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study. Int J Neuropsychopharmacol 22:616\u2013630. https:\/\/doi.org\/10.1093\/ijnp\/pyz039","journal-title":"Int J Neuropsychopharmacol"},{"key":"2361_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A et al (2019) Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 76:893\u2013903. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1189","journal-title":"JAMA Psychiatry"},{"key":"2361_CR10","doi-asserted-by":"publisher","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","volume":"81","author":"E Wajs","year":"2020","unstructured":"Wajs E, Aluisio L, Holder R et al (2020) Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study. J Clin Psychiatry 81:19m12891. https:\/\/doi.org\/10.4088\/JCP.19m12891","journal-title":"J Clin Psychiatry"},{"key":"2361_CR11","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","volume":"48","author":"N Zaki","year":"2023","unstructured":"Zaki N, Popova V, Daly EJ et al (2023) Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology 48:1225\u20131233. https:\/\/doi.org\/10.1038\/s41386-023-01577-5","journal-title":"Neuropsychopharmacology"},{"key":"2361_CR12","doi-asserted-by":"publisher","first-page":"pyaf027","DOI":"10.1093\/ijnp\/pyaf027","volume":"28","author":"N Zaki","year":"2025","unstructured":"Zaki N, Chen C, Fu DJ et al (2025) Safety and efficacy with esketamine in treatment-resistant depression: final results of the SUSTAIN-3 study. Int J Neuropsychopharmacol 28:pyaf027. https:\/\/doi.org\/10.1093\/ijnp\/pyaf027","journal-title":"Int J Neuropsychopharmacol"},{"key":"2361_CR13","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","volume":"389","author":"A Reif","year":"2023","unstructured":"Reif A, Bitter I, Buyze J et al (2023) Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med 389:1298\u20131309. https:\/\/doi.org\/10.1056\/NEJMoa2304145","journal-title":"N Engl J Med"},{"key":"2361_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jamapsychiatry.2025.1317","volume":"82","author":"A Janik","year":"2025","unstructured":"Janik A, Qiu X, Lane R et al (2025) Esketamine monotherapy in adults with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 82:877\u2013887. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.1317","journal-title":"JAMA Psychiatry"},{"key":"2361_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","volume":"319","author":"G Martinotti","year":"2022","unstructured":"Martinotti G, Vita A, Fagiolini A et al (2022) Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). J Affect Disord 319:646\u2013654. https:\/\/doi.org\/10.1016\/j.jad.2022.09.043","journal-title":"J Affect Disord"},{"key":"2361_CR16","doi-asserted-by":"publisher","first-page":"121257","DOI":"10.1016\/j.jad.2026.121257","volume":"401","author":"C de Oliveira Lapa","year":"2026","unstructured":"de Oliveira Lapa C, Viola T, Delfino R et al (2026) Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: evidence from real-world studies. J Affect Disord 401:121257. https:\/\/doi.org\/10.1016\/j.jad.2026.121257","journal-title":"J Affect Disord"},{"key":"2361_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1176\/appi.ajp.20240655","volume":"182","author":"G Sanacora","year":"2025","unstructured":"Sanacora G, Ahmed M, Brown B et al (2025) Real-world safety of esketamine nasal spray: a comprehensive analysis almost 5 years after first approval. Am J Psychiatry 182:913\u2013921. https:\/\/doi.org\/10.1176\/appi.ajp.20240655","journal-title":"Am J Psychiatry"},{"key":"2361_CR18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1745-6924.2008.00088.x","volume":"3","author":"S Nolen-Hoeksema","year":"2008","unstructured":"Nolen-Hoeksema S, Wisco BE, Lyubomirsky S (2008) Rethinking rumination. Perspect Psychol Sci 3:400\u2013424. https:\/\/doi.org\/10.1111\/j.1745-6924.2008.00088.x","journal-title":"Perspect Psychol Sci"},{"key":"2361_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.brat.2010.12.006","volume":"49","author":"KA McLaughlin","year":"2011","unstructured":"McLaughlin KA, Nolen-Hoeksema S (2011) Rumination as a transdiagnostic factor in depression and anxiety. Behav Res Ther 49:186\u2013193. https:\/\/doi.org\/10.1016\/j.brat.2010.12.006","journal-title":"Behav Res Ther"},{"key":"2361_CR20","doi-asserted-by":"publisher","first-page":"103573","DOI":"10.1016\/j.brat.2020.103573","volume":"127","author":"ER Watkins","year":"2020","unstructured":"Watkins ER, Roberts H (2020) Reflecting on rumination: consequences, causes, mechanisms and treatment of rumination. Behav Res Ther 127:103573. https:\/\/doi.org\/10.1016\/j.brat.2020.103573","journal-title":"Behav Res Ther"},{"key":"2361_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1192\/bjp.bp.110.090282","volume":"199","author":"ER Watkins","year":"2011","unstructured":"Watkins ER, Mullan E, Wingrove J et al (2011) Rumination-focused cognitive-behavioural therapy for residual depression: phase II randomized controlled trial. Br J Psychiatry 199:317\u2013322. https:\/\/doi.org\/10.1192\/bjp.bp.110.090282","journal-title":"Br J Psychiatry"},{"key":"2361_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1037\/0021-843X.102.1.20","volume":"102","author":"S Nolen-Hoeksema","year":"1993","unstructured":"Nolen-Hoeksema S, Morrow J, Fredrickson BL (1993) Response styles and the duration of episodes of depressed mood. J Abnorm Psychol 102:20\u201328. https:\/\/doi.org\/10.1037\/0021-843X.102.1.20","journal-title":"J Abnorm Psychol"},{"key":"2361_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000443699","volume":"85","author":"L Jelinek","year":"2016","unstructured":"Jelinek L, Hauschildt M, Wittekind CE et al (2016) Efficacy of metacognitive training for depression: a randomized controlled trial. Psychother Psychosom 85:231\u2013234. https:\/\/doi.org\/10.1159\/000443699","journal-title":"Psychother Psychosom"},{"key":"2361_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/bjc.12213","volume":"58","author":"L Jelinek","year":"2019","unstructured":"Jelinek L, Faissner M, Moritz S, Kriston L (2019) Long-term efficacy of metacognitive training for depression (D-MCT): a randomized controlled trial. Br J Clin Psychol 58:245\u2013259. https:\/\/doi.org\/10.1111\/bjc.12213","journal-title":"Br J Clin Psychol"},{"key":"2361_CR25","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/cpp.2733","volume":"29","author":"M Hauschildt","year":"2022","unstructured":"Hauschildt M, Arlt S, Moritz S, Yassari AH, Jelinek L (2022) Efficacy of metacognitive training for depression as add-on intervention for patients with depression in acute intensive psychiatric inpatient care: a randomized controlled trial. Clin Psychol Psychother 29:1542\u20131555. https:\/\/doi.org\/10.1002\/cpp.2733","journal-title":"Clin Psychol Psychother"},{"key":"2361_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jad.2024.12.083","volume":"373","author":"S Moritz","year":"2025","unstructured":"Moritz S, Dietrichkeit M, Schmueser A, Hagemann-Goebel M, Jelinek L (2025) Metacognitive training for depression (D-MCT) compared to computerized cognitive remediation in outpatient care: a randomized controlled trial. J Affect Disord 373:175\u2013183. https:\/\/doi.org\/10.1016\/j.jad.2024.12.083","journal-title":"J Affect Disord"},{"key":"2361_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fpsyg.2017.00031","volume":"8","author":"R Hagen","year":"2017","unstructured":"Hagen R, Hjemdal O, Solem S et al (2017) Metacognitive therapy for depression in adults: a waiting list randomized controlled trial with six months follow-up. Front Psychol 8:31. https:\/\/doi.org\/10.3389\/fpsyg.2017.00031","journal-title":"Front Psychol"},{"key":"2361_CR28","doi-asserted-by":"publisher","first-page":"7878","DOI":"10.1038\/s41598-020-64577-1","volume":"10","author":"P Callesen","year":"2020","unstructured":"Callesen P, Reeves D, Heal C, Wells A (2020) Metacognitive therapy versus cognitive behaviour therapy in adults with major depression: a parallel single-blind randomised trial. Sci Rep 10:7878. https:\/\/doi.org\/10.1038\/s41598-020-64577-1","journal-title":"Sci Rep"},{"key":"2361_CR29","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3389\/fpsyg.2018.02211","volume":"9","author":"N Normann","year":"2018","unstructured":"Normann N, Morina N (2018) The efficacy of metacognitive therapy: a systematic review and meta-analysis. Front Psychol 9:2211. https:\/\/doi.org\/10.3389\/fpsyg.2018.02211","journal-title":"Front Psychol"},{"key":"2361_CR30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1080\/16506073.2024.2434920","volume":"54","author":"E Andersson","year":"2025","unstructured":"Andersson E, Aspvall K, Schettini G et al (2025) Efficacy of metacognitive interventions for psychiatric disorders: a systematic review and meta-analysis. Cogn Behav Ther 54:276\u2013302. https:\/\/doi.org\/10.1080\/16506073.2024.2434920","journal-title":"Cogn Behav Ther"},{"key":"2361_CR31","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/jcm15041629","volume":"15","author":"V Martiadis","year":"2026","unstructured":"Martiadis V, Raffone F, Testa S et al (2026) Integrating psychiatric, psychotherapeutic, and nursing care in intranasal esketamine for treatment-resistant depression. J Clin Med 15:1629. https:\/\/doi.org\/10.3390\/jcm15041629","journal-title":"J Clin Med"},{"key":"2361_CR32","doi-asserted-by":"publisher","first-page":"104983","DOI":"10.1016\/j.ajp.2026.104983","volume":"120","author":"F Raffone","year":"2026","unstructured":"Raffone F, Mazzoni F, De Ciechi A et al (2026) Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: a real-world longitudinal study of suicidal ideation and self-harm. Asian J Psychiatr 120:104983. https:\/\/doi.org\/10.1016\/j.ajp.2026.104983","journal-title":"Asian J Psychiatr"},{"key":"2361_CR33","doi-asserted-by":"publisher","first-page":"120231","DOI":"10.1016\/j.jad.2025.120231","volume":"392","author":"M Olivola","year":"2026","unstructured":"Olivola M, Mazzoni F, Tarantino B et al (2026) Mentalization and emotional-cognitive rigidity as predictors of esketamine\u2019s effects on treatment-resistant depression: findings from a prospective observational study. J Affect Disord 392:120231. https:\/\/doi.org\/10.1016\/j.jad.2025.120231","journal-title":"J Affect Disord"},{"key":"2361_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tins.2011.11.004","volume":"35","author":"RS Duman","year":"2012","unstructured":"Duman RS, Voleti B (2012) Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 35:47\u201356. https:\/\/doi.org\/10.1016\/j.tins.2011.11.004","journal-title":"Trends Neurosci"},{"key":"2361_CR35","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould TD (2018) Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 23:801\u2013811. https:\/\/doi.org\/10.1038\/mp.2017.255","journal-title":"Mol Psychiatry"},{"key":"2361_CR36","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. PLoS Med 4:e296. https:\/\/doi.org\/10.1371\/journal.pmed.0040296","journal-title":"PLoS Med"},{"key":"2361_CR37","unstructured":"European Medicines Agency (2024) Spravato (esketamine): EPAR product information. European Medicines Agency, Amsterdam. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spravato Accessed 18 May 2026"},{"key":"2361_CR38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, \u00c5sberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382\u2013389. https:\/\/doi.org\/10.1192\/bjp.134.4.382","journal-title":"Br J Psychiatry"},{"key":"2361_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1023910315561","volume":"27","author":"W Treynor","year":"2003","unstructured":"Treynor W, Gonzalez R, Nolen-Hoeksema S (2003) Rumination reconsidered: a psychometric analysis. Cognit Ther Res 27:247\u2013259. https:\/\/doi.org\/10.1023\/A:1023910315561","journal-title":"Cognit Ther Res"},{"key":"2361_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0165-0327(02)00120-9","volume":"77","author":"MJ M\u00fcller","year":"2003","unstructured":"M\u00fcller MJ, Himmerich H, Kienzle B, Szegedi A (2003) Differentiating moderate and severe depression using the Montgomery-\u00c5sberg Depression Rating Scale (MADRS). J Affect Disord 77:255\u2013260. https:\/\/doi.org\/10.1016\/S0165-0327(02)00120-9","journal-title":"J Affect Disord"},{"key":"2361_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/wps.20701","volume":"19","author":"P Cuijpers","year":"2020","unstructured":"Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA (2020) A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry 19:92\u2013107. https:\/\/doi.org\/10.1002\/wps.20701","journal-title":"World Psychiatry"},{"key":"2361_CR42","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jad.2016.01.036","volume":"194","author":"E Karyotaki","year":"2016","unstructured":"Karyotaki E, Smit Y, Henningsen KH et al (2016) Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. J Affect Disord 194:144\u2013152. https:\/\/doi.org\/10.1016\/j.jad.2016.01.036","journal-title":"J Affect Disord"},{"key":"2361_CR43","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jamapsychiatry.2020.3650","volume":"78","author":"J Guidi","year":"2021","unstructured":"Guidi J, Tomba E, Ostuzzi G et al (2021) Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder: a systematic review and meta-analysis. JAMA Psychiatry 78:261\u2013269. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3650","journal-title":"JAMA Psychiatry"},{"key":"2361_CR44","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1017\/S0033291716002774","volume":"47","author":"K Kamenov","year":"2017","unstructured":"Kamenov K, Twomey C, Cabello M, Prina AM, Ayuso-Mateos JL (2017) The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. Psychol Med 47:414\u2013425. https:\/\/doi.org\/10.1017\/S0033291716002774","journal-title":"Psychol Med"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-026-02361-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:49:06Z","timestamp":1789051746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-026-02361-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1007\/s00406-026-02361-4","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Pavia (approval no. 84157\/21, 27 August 2021), with subsequent approved amendments covering the present observational recruitment period. The recruitment period for the present analysis was January-June 2025. The study was not registered in ClinicalTrials.gov or the EU Clinical Trials Register. All participants provided written informed consent. The procedures were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidance.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants prior to inclusion in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}